|
20 May 2020 |
Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic
|
|
20 May 2020 |
Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)
|
|
14 May 2020 |
Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities
|
|
14 May 2020 |
DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study
|
|
14 May 2020 |
Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial
|
|
13 May 2020 |
Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
|
|
12 May 2020 |
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
|
|
08 May 2020 |
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
|
|
07 May 2020 |
Molecular Partners Confirms Ultra-Potent Inhibition of SARS-CoV-2 Live Virus by Anti-COVID-19 DARPin Candidates
|
